Evaluation of Genetic Variations in miRNA-Binding Sites of BRCA1 and BRCA2 Genes as Risk Factors for the Development of Early-Onset and/or Familial Breast Cancer |
Erturk, Elif
(Department of Medical Biology, Faculty of Medicine, Uludag University)
Cecener, Gulsah (Department of Medical Biology, Faculty of Medicine, Uludag University) Polatkan, Volkan (Department of General Surgery, Faculty of Medicine, Uludag University) Gokgoz, Sehsuvar (Department of General Surgery, Faculty of Medicine, Uludag University) Egeli, Unal (Department of Medical Biology, Faculty of Medicine, Uludag University) Tunca, Berrin (Department of Medical Biology, Faculty of Medicine, Uludag University) Tezcan, Gulcin (Department of Medical Biology, Faculty of Medicine, Uludag University) Demirdogen, Elif (Department of Medical Biology, Faculty of Medicine, Uludag University) Ak, Secil (Department of Medical Biology, Faculty of Medicine, Uludag University) Tasdelen, Ismet (Department of General Surgery, Faculty of Medicine, Uludag University) |
1 | Egeli U, Cecener G, Tunca B, Tasdelen I (2006). Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives. Cancer Invest, 24, 484-91. DOI |
2 | Erturk E, Cecener G, Egeli U, et al (2014). Expression status of let-7a and miR-335 among breast tumors in patients with and without germ-line BRCA mutations. Mol and Cell Biochem. |
3 | Esquela-Kerscher A, Slack FJ (2006). Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer, 6, 259-69. DOI ScienceOn |
4 | Ferla R, Calo V (2007). Founder mutations in BRCA1 and BRCA2 genes. Ann Oncol, 18, 93-8. |
5 | Hayashita Y, Osada H, Tatematsu Y, et al (2005). A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res, 65, 9628-32. DOI ScienceOn |
6 | Ford D, Easton DF, Stratton M, et al (1998). Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet, 62, 676-89. DOI ScienceOn |
7 | Goto Y, Yue L, Yokoi A, et al (2001). A novel single-nucleotide polymorphism in the 3'-untranslated region of the human dihydrofolate reductase gene with enhanced expression. Clin Cancer Res, 7, 1952-6. |
8 | Hafez MM, Hassan ZK, Zekri AR, et al (2012). MicroRNAs and metastasis-related gene expression in Egyptian breast cancer patients. Asian Pac J Cancer Prev, 13, 591-8. DOI |
9 | He L, Thomson JM, Hemann MT, et al (2005). A microRNA polycistron as a potential human oncogene. Nature, 435, 828-33. DOI ScienceOn |
10 | Hennessy BT, Timms KM, Carey MS, et al (2010). Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol, 28, 3570-6. DOI |
11 | Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. DOI |
12 | Joseph S, Sellappa S, Prathyumnan S, Keyan KS (2011). A novel polymorphism in BRCA2 exon 8 and breast cancer risk in South India. Asian Pac J Cancer Prev, 12, 309-11. |
13 | Jovanovic M, Hengartner MO (2006). miRNAs and apoptosis: RNAs to die for. Oncogene, 25, 6176-87. DOI ScienceOn |
14 | Kayani Mu, Kayani MA, Malik FA, Faryal R (2011). Role of miRNAs in breast cancer. Asian Pac J Cancer Prev, 12, 3175-80. |
15 | Keen JC, Davidson NE (2003). The biology of breast carcinoma. Cancer, 97, 825-33. DOI ScienceOn |
16 | Kooshyar MM, Nassiri M, Mahdavi M, Doosti M, Parizadeh A (2013). Identification of germline BRCA1 mutations among breast cancer families in Northeastern Iran. Asian Pac J Cancer Prev, 14, 4339-45. DOI ScienceOn |
17 | Kenemans P, Verstraeten RA, Verheijen RH (2004). Oncogenic pathways in hereditary and sporadic breast cancer. Maturitas, 49, 34-43. DOI ScienceOn |
18 | Khana KK, Jackson SP (2001). DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet, 27, 247-54. DOI ScienceOn |
19 | Kontorovich T, Levy A, Korostishevsky M, Nir U, Friedman E (2010). Single nucleotide polymorphisms in miRNA binding sites and miRNA genes as breast/ovarian cancer risk modifiers in Jewish high-risk women. Int J Cancer, 127, 589-97. DOI |
20 | Li JY, Jia S, Zhang WH, et al (2013). Differential distribution of microRNAs in breast cancer grouped by clinicopathological subtypes. Asian Pac J Cancer Prev, 14, 3197-203. DOI ScienceOn |
21 | Lu J, Getz G, Miska EA, et al (2005). MicroRNA expression profiles classify human cancers. Nature, 435, 834-8. DOI ScienceOn |
22 | Miki Y, Swensen J, Shattuck-Eidens D, et al (1994). A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science, 266, 66-71. DOI |
23 | Nicoloso MS, Sun H, Spizzo R, et al (2010). Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. Cancer Res, 70, 2789-98. DOI |
24 | Nilsen TW (2007). Mechanisms of microRNA-mediated gene regulation in animal cells. Trends Genet, 23, 243-9. DOI ScienceOn |
25 | O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT (2005). c-MYC regulated microRNAs modulate E2F-1 expression. Nature, 435, 839-43. DOI ScienceOn |
26 | Pelletier C, Speed WC, Paranjape T, et al (2011). Rare BRCA1 haplotypes including 3'UTR SNPs associated with breast cancer risk. Cell Cycle, 10, 90-9. DOI ScienceOn |
27 | Sehl ME, Langer LR, Papp JC, et al (2009). Associations between single nucleotide polymorphisms in double-stranded DNA repair pathway genes and familial breast cancer. Clin Cancer Res, 15, 2192-203. DOI ScienceOn |
28 | Pongsavee M, Yamkamon V, Dakeng S, et al (2009). The BRCA1 3'-UTR: 5711?421T/T_5711?1286T/T genotype is a possible breast and ovarian cancer risk factor. Genet Test Mol Biomarkers, 13, 307-17. DOI ScienceOn |
29 | Scully R, Livingston DM (2000). In search of the tumoursuppressor functions of BRCA1 and BRCA2. Nature, 408, 429-32. DOI ScienceOn |
30 | Szabo CI, King MC (1997). Population genetics of BRCA1 and BRCA2. Am J Hum Genet, 60, 1013-20. |
31 | Wooster R, Bignell G, Lancaster J, et al (1995). Identification of the breast cancer susceptibility gene BRCA2. Nature, 378, 789-92. DOI ScienceOn |
32 | Wu W, Sun M, Zou GM, Chen J (2007). MicroRNA and cancer: current status and prospective. Int J Cancer, 120, 953-60. |
33 | Venkitaraman AR (2002). Cancer susceptibility and the functions of BRCA1and BRCA2. Cell, 108, 171-82. DOI ScienceOn |
34 | Zhang B, Pan X, Anderson TA (2006). MicroRNA: a new player in stem cells. J Cell Physiol, 209, 266-9. DOI |
35 | Brewster BL, Rossiello F, French JD, et al (2012). Identification of fifteen novel germline variants in the BRCA1 3'UTR reveals a variant in a breast cancer case that introduces a functional miR-103 target site. Hum Mutat, 33, 1665-75. DOI |
36 | Barroso E, Pita G, Arias JI, et al (2009). The Fanconi anemia family of genes and its correlation with breast cancer susceptibility and breast cancer features. Breast Cancer Res Treat, 118, 655-60. DOI ScienceOn |
37 | Betel D, Koppal A, Agius P, Sander C, Leslie C (2010). Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol, 11, 8-11. DOI |
38 | Chen Y, Lee W, Chew HK (1999). Emerging roles of BRCA1 in transcriptional regulation and DNA repair. J Cell Physiol, 181, 385-92. DOI |
39 | Cazzola M, Skoda RC (2000). Translational pathophysiology: a novel molecular mechanism of human disease. Blood, 95, 3280-88. |
40 | Cecener G, Egeli U, Tunca B, et al (2014). BRCA1/2 germline mutations and their clinical importance in Turkish breast cancer patients. Cancer Invest, 1-13. |
41 | Claus EB, Risch N, Thompson WD (1991). Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet, 48, 232-42. |
42 | Conne B, Stutz A, Vassalli JD (2000). The 3'-untranslated region of messenger RNA: a molecular "hot spot" for pathology? Nat Med, 6, 637-41. DOI ScienceOn |
43 | Downs-Holmes C, Silverman P (2011). Breast cancer: overview and updates. The Nurse Practitioner, 36, 20-6. |
44 | Peto I, Collins N, Barfoot R, et al (1999). Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst, 91, 943-9. DOI |